LCI News and Press, Lannett Co Inc From 11/30/20

Using cash on hand, Lannett Company (LCI) has fully repaid the remaining outstanding balance of $42M in its Term A Loans.CEO Tim Crew says, "Paying off our Term A Loans is an important achievement and a key step toward strengthening our balance sheet and improving our long-term financial heal...

Lannett Pays Off, In Full, Remaining Term A Loans PR Newswire PHILADELPHIA, Nov. 30, 2020 PHILADELPHIA , Nov. 30, 2020 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that the company used a portion of its existing cash on hand to pay o...

Gainers: Oncternal Therapeutics (ONCT) +131%, Aptevo Therapeutics (APVO) +42%, Aurora Cannabis (ACB) +36%, Tilray (TLRY) +29%, Akerna (KERN) +26%.Losers: Clovis Oncology (CLVS) -21%, bluebird bio (BLUE) -17%, Lannett Compan...

Image source: The Motley Fool. Lannett Inc (NYSE: LCI) Q1 2021 Earnings Call Nov 4, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Lannett Inc (LCI) Q1 2021 Earnings Call Transcript

Lannett Company, Inc. (LCI) Q1 2021 Results Conference Call November 04, 2020 04:30 PM ET Company Participants Robert Jaffe - IR Tim Crew - CEO John Kozlowski - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Gary Nachman - BMO Capital Markets Scott Henry - Roth Capi...

Lannett (LCI): FQ1 Non-GAAP EPS of $0.06 misses by $0.04; GAAP EPS of -$0.17 misses by $0.20.Revenue of $126.48M (-0.7% Y/Y) misses by $2.46M.Press Release For further details see: Lannett EPS misses by $0.04, misses on revenue

Lannett Announces Fiscal 2021 First-quarter Financial Results; Affirms Guidance Financial and Business Highlights: - Q1 Net Sales of $126 Million - Q1 Adjusted EBITDA of $33 Million - Commenced Marketing Four Products in FY21 Q1 - Fully Implemented $15 Million of...

Lannett (NYSE:LCI) is scheduled to announce FQ1 earnings results on Wednesday, November 4th, after market close.The consensus EPS Estimate is $0.10 (-54.5% Y/Y) and the consensus Revenue Estimate is $128.94M (+1.3% Y/Y).Over the last 2 years, LCI has beaten EPS estimates 75% of the time and h...

Lannett (LCI) launched the authorized generic of Tirosint (Levothyroxine Sodium Capsules USP) and inked an exclusive U.S. distribution agreement with Switzerland-based IBSA Institut Biochimique, a global pharmaceutical company.Under the agreement, Lannett will primarily provide sale...

Lannett Launches Authorized Generic of Tirosint® (Levothyroxine Sodium Capsules) --Unique Oral Formulation of Levothyroxine Expands Thyroid Deficiency Product Portfolio-- PR Newswire PHILADELPHIA, Nov. 3, 2020 PHILADELPHIA , Nov. 3, 2020 /PRNewsw...